» Articles » PMID: 16194284

The Diagnostic Interview for Psychoses (DIP): Development, Reliability and Applications

Overview
Journal Psychol Med
Specialty Psychology
Date 2005 Oct 1
PMID 16194284
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We describe the development, reliability and applications of the Diagnostic Interview for Psychoses (DIP), a comprehensive interview schedule for psychotic disorders.

Method: The DIP is intended for use by interviewers with a clinical background and was designed to occupy the middle ground between fully structured, lay-administered schedules, and semi-structured, psychiatrist-administered interviews. It encompasses four main domains: (a) demographic data; (b) social functioning and disability; (c) a diagnostic module comprising symptoms, signs and past history ratings; and (d) patterns of service utilization and patient-perceived need for services. It generates diagnoses according to several sets of criteria using the OPCRIT computerized diagnostic algorithm and can be administered either on-screen or in a hard-copy format.

Results: The DIP proved easy to use and was well accepted in the field. For the diagnostic module, inter-rater reliability was assessed on 20 cases rated by 24 clinicians: good reliability was demonstrated for both ICD-10 and DSM-III-R diagnoses. Seven cases were interviewed 2-11 weeks apart to determine test-retest reliability, with pairwise agreement of 0.8-1.0 for most items. Diagnostic validity was assessed in 10 cases, interviewed with the DIP and using the SCAN as 'gold standard': in nine cases clinical diagnoses were in agreement.

Conclusions: The DIP is suitable for use in large-scale epidemiological studies of psychotic disorders, as well as in smaller studies where time is at a premium. While the diagnostic module stands on its own, the full DIP schedule, covering demography, social functioning and service utilization makes it a versatile multi-purpose tool.

Citing Articles

Protocol for Cancloz: multicentre randomised, placebo-controlled, double-blind, parallel-group adaptive trial of cannabidiol for clozapine-resistant schizophrenia.

Siskind D, Bull C, Suetani S, Warren N, Suraev A, McGregor I BJPsych Open. 2024; 10(5):e156.

PMID: 39359160 PMC: 11536212. DOI: 10.1192/bjo.2024.748.


Elevated serum kynurenic acid in individuals with first-episode psychosis and insufficient response to antipsychotics.

Hatzimanolis A, Foteli S, Xenaki L, Selakovic M, Dimitrakopoulos S, Vlachos I Schizophrenia (Heidelb). 2024; 10(1):61.

PMID: 38987245 PMC: 11237022. DOI: 10.1038/s41537-024-00483-z.


Revisiting delusion subtypes in schizophrenia based on their underlying structures.

van der Vaart A, Ma Y, Chiappelli J, Bruce H, Kvarta M, Warner A J Psychiatr Res. 2024; 171:75-83.

PMID: 38246028 PMC: 10923062. DOI: 10.1016/j.jpsychires.2023.12.025.


Diminished social motivation in early psychosis is associated with polygenic liability for low vitamin D.

Hatzimanolis A, Tosato S, Ruggeri M, Cristofalo D, Mantonakis L, Xenaki L Transl Psychiatry. 2024; 14(1):36.

PMID: 38238289 PMC: 10796745. DOI: 10.1038/s41398-024-02750-0.


miRNA cargo in circulating vesicles from neurons is altered in individuals with schizophrenia and associated with severe disease.

Barnett M, Reay W, Geaghan M, Kiltschewskij D, Green M, Weidenhofer J Sci Adv. 2023; 9(48):eadi4386.

PMID: 38019909 PMC: 10686555. DOI: 10.1126/sciadv.adi4386.